CN113840624A - 单醣标记的纳米脂质体药物递送系统，其制法及其作为药物靶定递送载体的应用 - Google Patents

单醣标记的纳米脂质体药物递送系统，其制法及其作为药物靶定递送载体的应用 Download PDF

Info

Publication number
CN113840624A
CN113840624A CN201980096444.0A CN201980096444A CN113840624A CN 113840624 A CN113840624 A CN 113840624A CN 201980096444 A CN201980096444 A CN 201980096444A CN 113840624 A CN113840624 A CN 113840624A
Authority
CN
China
Prior art keywords
monosaccharide
nanoliposome
drug
liposome
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980096444.0A
Other languages
English (en)
Inventor
骆俊良
余律谊
沈耀安
洪上淯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fama Technology Consulting Co ltd
Original Assignee
Fama Technology Consulting Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fama Technology Consulting Co ltd filed Critical Fama Technology Consulting Co ltd
Publication of CN113840624A publication Critical patent/CN113840624A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof

Abstract

本发明关于一种单醣标记纳米脂质体药物递送系统，其作用为靶定分子的单醣配体与胆固醇分子结合，且经单醣‑修饰的胆固醇嵌入脂质体的双层膜结构中。本发明的葡萄糖胺标记纳米脂质体可将所携载的药物带至目标细胞，例如肿瘤组织癌细胞与癌干细胞，并通过胞吞作用使药物进入目标细胞中，而产生直接的毒杀作用或抑制干性基因表现，如此不仅可避免对正常细胞产生毒性，亦能有效提高癌症临床用药及放射疗法的治疗效果。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201980096444.0A 2019-05-23 2019-05-23 单醣标记的纳米脂质体药物递送系统，其制法及其作为药物靶定递送载体的应用 Pending CN113840624A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/088142 WO2020232701A1 (zh) 2019-05-23 2019-05-23 单醣标记的纳米脂质体药物递送系统,其制法及其作为药物靶定递送载体的应用

Publications (1)

Publication Number Publication Date
CN113840624A true CN113840624A (zh) 2021-12-24

Family

ID=73459286

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980096444.0A Pending CN113840624A (zh) 2019-05-23 2019-05-23 单醣标记的纳米脂质体药物递送系统，其制法及其作为药物靶定递送载体的应用

Country Status (3)

Country Link
US (1) US20220257514A1 (zh)
CN (1) CN113840624A (zh)
WO (1) WO2020232701A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115487306B (zh) * 2022-11-18 2023-03-17 深圳市华元生物技术股份有限公司 一种药物递送载体及其制备方法、应用、糖尿病治疗药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143267A1 (en) * 2002-01-30 2003-07-31 National Institute Of Advanced Industrial Sugar-modified liposome and products comprising the liposome
CN101406454A (zh) * 2008-11-14 2009-04-15 沈阳药科大学 低分子量壳聚糖修饰的脂质体及其制备方法
CN108517033A (zh) * 2018-06-13 2018-09-11 四川大学 一种新型双重脑靶向脂质材料及其在药物传递系统的应用
CN108743953A (zh) * 2018-06-13 2018-11-06 四川大学 一种新型双重脑肿瘤靶向脂质材料及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143267A1 (en) * 2002-01-30 2003-07-31 National Institute Of Advanced Industrial Sugar-modified liposome and products comprising the liposome
CN101406454A (zh) * 2008-11-14 2009-04-15 沈阳药科大学 低分子量壳聚糖修饰的脂质体及其制备方法
CN108517033A (zh) * 2018-06-13 2018-09-11 四川大学 一种新型双重脑靶向脂质材料及其在药物传递系统的应用
CN108743953A (zh) * 2018-06-13 2018-11-06 四川大学 一种新型双重脑肿瘤靶向脂质材料及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
聂华等: "酶促构建葡萄糖修饰脑靶向载紫杉醇脂质体制备处方及其工艺优化", 《中草药》, vol. 47, no. 11, pages 1867 - 1874 *

Also Published As

Publication number Publication date
US20220257514A1 (en) 2022-08-18
WO2020232701A1 (zh) 2020-11-26

Similar Documents

Publication Publication Date Title
Wang et al. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer
Chen et al. Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein
Tsukioka et al. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil)
Kim et al. Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment
Allahou et al. Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer
CN110522919B (zh) 甘露糖受体靶向的组合物、药物及其制备方法和应用
Jose et al. Polymeric lipid hybrid nanoparticles: properties and therapeutic applications
Zheng et al. Lipid-polymer nanoparticles for folate-receptor targeting delivery of doxorubicin
CN103479578B (zh) 一种马来酸匹杉琼的脂质体制剂及其制备工艺
US20040022842A1 (en) Liposome preparations containing oxaliplatin
CN106474064B (zh) 一种蒿甲醚纳米脂质体及其制备方法与应用
Dai et al. Biotin-conjugated multilayer poly [D, L-lactide-co-glycolide]-lecithin-polyethylene glycol nanoparticles for targeted delivery of doxorubicin
CN110123761A (zh) 一种仿生型高密度脂蛋白纳米粒及其制备和应用
Vanza et al. Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer
Gajbhiye et al. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics
Bangale et al. Stealth liposomes: a novel approach of targeted drug delivery in cancer therapy
Kumar et al. Novel drug delivery system
WO2012073125A1 (en) Tsh-conjugated nanocarrier for the treatment of thyroid cancer
CN107998081A (zh) 一种靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用
CN113840624A (zh) 单醣标记的纳米脂质体药物递送系统，其制法及其作为药物靶定递送载体的应用
CN109481400B (zh) 一种肝靶向阿霉素/Bcl-2 siRNA共载纳米胶束及其制备方法和应用
Ma et al. Novel theranostic zinc phthalocyanine–phospholipid complex self-assembled nanoparticles for imaging-guided targeted photodynamic treatment with controllable ROS production and shape-assisted enhanced cellular uptake
CN114099698B (zh) 一种pH敏感脂质体及其制备方法与应用
TWI734987B (zh) 單醣標記之奈米脂質體藥物遞送系統，其製法及其作為藥物靶定遞送載體之應用
US20220313820A1 (en) Ultrasound-assisted drug delivery carrier using ultrasound contrast agent containing ligand conjugated with drug through ester bond

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination